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since January 1st, 2011.The correlation coefficient was calculated to assess the linear 
correlation of the additional clinical benefit of an oncology product evaluated by the 
G-BA and the HAS, both measured by an arbitrary score scale from 1 (best outcome) 
to 5 (worst outcome). The G-BA score was taken from the “added benefit” rating, and 
the HAS score was determined by the ASMR rating. The additional clinical benefit is 
determined by the clinical data (efficacy, safety and QoL) provided in both GER and 
FRA. The correlation coefficient between the incremental OS benefit and the HTA 
appraisal outcome in each market was also calculated. Results: The correlation 
coefficient of HTA decisions by the G-BA and the HAS for oncology products is 0.73. 
In Germany, the magnitude of incremental OS benefit negatively correlates with 
the G-BA score (correlation coefficient = -0.83). Similar results were also observed 
in France, where the correlation coefficient between the incremental OS benefit 
and the HAS score was -0.66. Interestingly, the G-BA score forms clear “steps” that 
highly correlate with the incremental OS benefit based on our empirical analysis. 
To “step up” from score 3 to score 2, an incremental OS benefit of 3 months appears 
to serve as a threshold. ConClusions: The negative linear correlation between 
the incremental OS benefit and the HTA rating in GER and FRA suggests that the 
additional clinical benefit, especially the incremental OS benefit is a major factor 
in determining the HTA outcome in GER and FRA.
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BACkgRound: Health technology assessment (HTA) agencies summarize infor-
mation about the medical, social, economic and ethical issues related to the use 
of health technologies in a systematic, transparent, unbiased, and robust manner. 
Several global organizations exist to provide guidance based on clinical effective-
ness, safety, and cost-effectiveness relative to alternative technologies. oBjeCtives: 
We compared recommendations made by the pan-Canadian Oncology Drug 
Review (pCODR) to other HTA agencies. Methods: Publicly accessible recom-
mendations were reviewed: Australia (Pharmaceutical Benefits Advisory Committee 
(PBAC), www.pbs.gov.au), Canada (pCODR, www.pcodr.ca), Sweden (Dental and 
Pharmaceutical Benefits Agency (TLV), www.tlv.se) and UK (National Institute for 
Health and Care Excellence (NICE), www.nice.org.uk). Additional information was 
obtained from the www.reimbursementdecisions.com database. Results: pCODR 
had thirteen product reviews in common with PBAC, six with TLV, and thirteen with 
NICE. Overall, pCODR unlike the other agencies, was most likely to provide a positive 
recommendation, albeit, conditional on improvement of cost-effectiveness. In gen-
eral, negative recommendations made by pCODR based on clinical concerns were 
often mirrored by the other agencies. Similarly, findings by pCODR of positive clini-
cal benefit but with concerns over cost-effectiveness were often reciprocated by the 
other agencies in conditional positive recommendations (i.e., price reductions or risk 
sharing) or by negative recommendations due to cost-effectiveness. ConClusions: 
The recommendations by these agencies reflected significant agreement regarding 
overall clinical and economic benefit. Although discordance in recommendation 
wording between agencies was noted, these likely reflected process and funding dif-
ferences rather than a difference in the perceived product value. pCODR differs from 
other agencies in its clear distinction between evidence review and funding negotia-
tions. As such, pCODR can positively recommend a product with acceptable clinical 
value conditional on improved cost-effectiveness without specifying the degree of 
price reduction needed or negotiating such discounts. This creates an environment 
that favours early global launch in Canada without delays for price negotiation.
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The CaNCer laNdsCaPe iN brazil: a reTrosPeCTive aNalysis of 
braziliaN NaTioNal iNsTiTuTe of CaNCer PaTieNT regisTry daTabase 
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oBjeCtives: Cancer is the second lead cause of death in Brazil, with growing social 
and economic burden. According to Brazilian National Institute of Cancer/INCA, 
576.580 new cases are expected in 2014. This study aimed better understand oncol-
ogy landscape in Brazil using a real-world data source. Methods: Data reported 
from 2009-2013 was taken from RHC-INCA – an open national patient registry data-
base – for the following cancers: gastric (GC/ICD16); colorectal (CRC/ICD18-21); lung 
(LC/ICD33-34); breast (BC/ICD50); cervical (CC/ICD53) and ovarian (OC/ICD56). Only 
adult patients with TNM classification at diagnosis were included. Records labeled 
as ‘not informed’ or ‘not applicable’ were excluded. This study assessed distribution 
of those cancers according to gender; age group; stage at diagnosis for all patients; 
treatment choice and 1-year outcomes in stage IV patients with non-recorded previ-
ous treatment. Results: Gender (male/female): GC–65.2%/34.8%; CRC–48.3%/51.7%; 
LC–62.2%/37.8%; BC–1.3%/98.7%. Highest frequency ages: males GC–60-74 years; 
CRC–55-69 years; LC–55-74 years; females GC–55-69 years; CRC–55-69 years; LC–55-
69 years; BC–45-59 years; CC–35-49 years; OC–45-59 years. Stage at diagnosis (0/I/
II/III/IV): GC–0.3%/10.7%/13.9%/24.8%/50.3%; CRC–0.6%/8.7%/29.5%/35.5%/25.7%; 
LC–0.1%/5.3%/6.2%/37.0%/51.4%; BC–3.0%/19.1%/36.8%/32.2%/8.8%; CC–17.5%/1
5.6%/26.3%/34.2%/6.3%; OC–0.0%/25.0%/8.5%/41.9%/24.6%. Regions with highest 
frequency of advanced cases (stages III/IV): GC–North(83.3%); CRC–South(65.1%); 
North(64.6%); LC–North(91.6%) and Northeast(91.1%); BC–North(52.2%) and 
West Center(51.6%); CC–South(49.3%) and North(45.8%); OC–South(69.9%); 
Northeast(67.3%). Stage IV treatment choice (chemotherapy alone or combined 
with another procedure/non-chemotherapy procedures): GC–73.4%/26.6%; CRC–
81.3%/18.7%; LC–75.1%/24.9%; BC–76.6%/23.4%; CC–63.5%/36.5%; OC–83.5%/16.5%. 
1-year outcomes (remission or controlled disease/progression, therapy unfeasibil-
ity or death): GC–26.9%/73.1%; CRC–34.3%/65.7%; LC–22.7%/77.3%; BC–38.4%/61.6%; 
CC–34.6%/65.4%; OC–35.1%/64.9%. ConClusions: Results evidence epidemiological 
differences between each type of cancer and amongst country regions. Regarding 
metastatic disease the majority of treatment strategies include chemotherapy; 
furthermore outcomes are poor with less than 40% of patients in remission or 
controlled disease after first year of treatment. The study had limitation regarding 
that São Paulo state data are not included in RHC-INCA.
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oBjeCtives: To assess the impact on medical decision-making by an in-vitro diag-
nostic test that predicts the risk of clinically recurrent prostate cancer following 
prostatectomy. Methods: ProsVue™ is an FDA-cleared prognostic test that meas-
ures the linear slope of 3 ultrasensitive prostate-specific antigen levels over time. 
In the 510(k) clinical study, ProsVue was the strongest independent predictor of 
clinically recurrent prostate cancer in a 304-man cohort study. However, its clini-
cal utility in adjuvant treatment decision-making has not yet been demonstrated. 
We prospectively enrolled men treated by radical prostatectomy in a multicenter, 
IRB-approved clinical trial. At postsurgical followup, urologist investigators (N= 17) 
stratified each of their patients into a low, intermediate or high risk group for cancer 
recurrence based on clinicopathologic findings and documented their initial treat-
ment plan. We employed the CAPRA-S postprostatectomy nomogram to standardize 
risk assessments across the investigative sites. After a patient’s ProsVue result was 
reported, urologists recorded whether or not the patient’s initial treatment plan was 
changed. The proportion of cases referred for secondary treatment before and after 
ProsVue and the significance of the difference was determined. Results: Of 225 
men reported; 128 (56.9%) were stratified into intermediate and high CAPRA-S risk 
groups. Investigators reported that they would have referred 41/128 (32.0%) at-risk 
men for adjuvant radiotherapy without ProsVue information. After results were 
known, investigators referred only 15/128 (11.7%) men. The difference in proportions 
(-20.3%, 95% confidence interval [CI] -29.9 to -10.3%) is significant (p < 0.0001). Odds 
of a referral after the ProsVue result was reported was significantly reduced (Odds 
Ratio = 0.28, 95% CI 0.15 to 0.54, p < 0.0001). ConClusions: ProsVue has significant 
clinical utility in high-risk postprostatectomy cancer patients. A ProsVue result ≤ 2.0 
pg/mL/month significantly reduced the proportion of urologists’ recommendations 
for adjuvant radiotherapy. Followup studies are needed to demonstrate whether or 
not ProsVue utilization reduces health care costs.
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oBjeCtives: Relatively little is known about physicians’ decisions to adopt and 
use GEP to aid in treatment recommendations. The objective of this study was to 
determine the association between specific characteristics of a GEP assay, Oncotype 
DX and oncologists’ intention to use this assay in making treatment recommen-
dations for breast cancer patients. Methods: A nationally representative sam-
ple of oncologists treating breast cancer patients was surveyed. Linear regression 
analysis was performed to establish the association between physicians’ per-
ceptions and intentions to use Oncotype DX. Results: A total of 119 completed 
surveys were received yielding a response rate of 44.1%. Of the Oncotype DX test 
characteristics evaluated, ‘validity of the test’ (p= 0.006) and ‘use of Oncotype DX 
by fellow Oncologists’ (p= 0.0068) were significantly associated with oncologists’ 
use of the assay. Oncologists’ intention to use Oncotype DX increased consist-
ently with their perceptions about its usefulness (β = 0.222). Insurance status of 
the patients was also significantly associated with physicians’ use of Oncotype DX 
(p= 0.008). ConClusions: We report a novel application of an adapted technology 
acceptance model to understand decision-making by oncologists who treat breast 
cancer patients surrounding the use of GEP in making treatment recommendations. 
Our study provides insights into the characteristics and innovation factors of a 
particular genomic diagnostic that affect decision-making by oncologists who treat 
breast cancer patients. Our findings have implications for knowledge translation 
efforts related to molecular genomic diagnostics and to the development of future 
molecular genomic diagnostics.
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oBjeCtives: Overall objectives are to examine symptom burden and quality of life 
in prospectively accrued patients with advanced non-small cell lung cancer (NSCLC), 
treated in real world settings. The present report examines treatment patterns and 
baseline characteristics of an initial sample of 95 patients. Methods: Patients 
starting first line treatment of stage IIIB/IV NSCLC were prospectively accrued and 
consented at 30 US-based community oncology settings. Eligible patients received 
one of four regimens: A: pemetrexed with cisplatin or carboplatin; B: bevacizumab 
with chemotherapy doublet; C: chemotherapy doublet; D: bevacizumab, pemetrexed 
and carboplatin. Site staff collected baseline demographic and clinical informa-
tion, and patient-reported outcome and symptom measures at baseline and each 
office visit. Overall target enrollment is 225. Results: Of 95 patients, 40 (42%) were 
accrued in Regimen A, 17 (17.9%) in Regimen B, 13 (13.7%) in Regimen C, and 25 
(26.3%) in Regimen D. Patients were 54.7% male, 87.4% Caucasian, with mean age 
64.6 (±11.7). 15.8% had impaired performance status (ECOG 2+ or equivalent), with 
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82.1% initially diagnosed at stage IV. Common sites of metastasis were bone (41.1%), 
brain (23.2%), contralateral lung (19.0%), and liver (15.8%). 24.2% were current smok-
ers; 67.4% past (median 38 pack years). There were no differences in these character-
istics by regimen. The most common comorbidities were COPD (30.5%) and diabetes 
(16.8%). Most patients were from the South (56.8%) vs. Northeast (13.7%), Midwest 
(21.1%), and West (8.4%). Patients from the South were 3 times as likely (OR = 3.02) 
to receive a bevacizumab-containing regimen (Regimens B+D) than patients from 
the non-South regions, χ 2 = 6.5293, df = 1, p = 0.0106. ConClusions: Patients treated 
for advanced NSCLC in real world settings appear demographically and clinically 
similar to patients treated in clinical trials. Preliminary findings suggest regional 
differences in chemotherapeutic treatment patterns.
CardiovasCular disorders – Clinical outcomes studies
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Ali A.K.
Eli Lilly and Company, Indianapolis, IN, USA
oBjeCtives: There has been an increasing concern about the link between statins 
and the risk for cataract. This study detects and clarifies signals of cataract forma-
tion and operation associated with lipid-lowering drugs (LLD), including statins, from 
postmarketing adverse event reports. Methods: A pharmacovigilance analysis 
of adverse events submitted to the FDA Adverse Event Reporting System between 
Oct1997 and Sep2012 was conducted. Multi-item Gamma Poisson Shrinker algorithm 
was applied to detect signals of cataract and cataract operation. Empirical Bayes 
Geometric Mean (EBGM) and corresponding 95%CI (EB05-EB95) were estimated for 
drug-event combinations of interest. Estimates with EB05≥ 2 are significant dispro-
portional reporting of the event for LLD. The MedDRA Preferred Term hierarchy was 
used to define events, and generic name of the reported drug was used to define LLD 
exposure. Results: 1,195 cataract and 99 cataract operation reports were submitted 
for LLD (respectively, 94% and 95% of these reports were for statins). Most of cataract 
reports were for lovastatin (n= 399) and most of cataract operation reports were for 
atorvastatin (n= 68). Among LLD, cataract signal was detected for statins (EBGM 3.64, 
EB05-EB95 3.18-4.2). Among statins, lovastatin was associated with the strongest sig-
nal for cataract formation (EBGM 12.8, EB05-EB95 11.8-14.0), followed by pravastatin 
(EBGM 3.82, EB05-EB95 3.21-4.53) and atorvastatin (EBGM 2.95, EB05-EB95 2.7-3.21). No 
cataract operation signal was detected for any LLD class, including statins (EBGM 1.52, 
EB05-EB95 1.08-2.36); however, cataract operation signals were detected for rosuvas-
tatin (EBGM 3.82, EB05-EB95 3.21-4.53) and atorvastatin (EBGM 3.33, EB95-EB95 2.72-
4.05). Disproportional reporting of cataract with EB05> 1 was found for simvastatin 
(EB05= 1.66), fluvastatin (EB05= 1.34) and gemfibrozil (EB05= 1.32). ConClusions: 
Antilipemic treatment with statins may be associated with an increased risk of cata-
ract development or operation. Statin users with risk factors for cataract formation 
should have routine ophthalmic examination for lenticular opacity, and alternative 
LLD should be used in high-risk individuals.
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oBjeCtives: During the last decade, the standard of care to treat acute coronary 
syndrome (ACS) patients was typically a combination of clopidogrel and aspirin. 
However, newer antiplatelet agents were approved recently. The aim of this study 
was to assess the effect on time-to-readmission and resource utilization of prasu-
grel vs. clopidogrel in prasugrel treated patients after hospitalization with an ACS 
event. Methods: Based on the Truven Health Analytics MarketScan database 
from January 2009 through July 2012 a matched-cohort was created. Inferences 
for average treatment effect on time-to-readmission and numbers of hospitaliza-
tions, ER visits, and outpatient visits in prasugrel treated patients at 30 days and 
1 year were performed by (1) frequentist Kaplan-Meier estimation with a log-rank 
test and Lin’s method for censored resource utilization outcomes; and (2) Bayesian 
discrete-time hazard models and negative binomial models. Bayes factors were 
also determined. Results: 10,963 matched-pairs were well-balanced on baseline 
characteristics. Frequentist analyses of time-to-readmission at 1 year and resource 
utilization rates over 30 and 365 days showed no statistical differences between 
prasugrel and clopidogrel (log-rank test and Lin method p-values all > 0.05 ). The 
posterior probability of equivalence between drugs for time-to-readmission at a 
margin of 10% was 98.7%, and based on the Bayes factor for superiority there is 
little evidence of superiority. Based on Bayesian analyses of resource utilization 
outcomes there are high probabilities of equivalence at a margin of 10% and little 
evidence of superiority for all outcomes except for number of hospitalizations at 30 
days, for which there is positive evidence that clopidogrel is superior to prasugrel, 
although the probability that prasugrel is non-inferior to clopidogrel at the 10% 
margin is 0.765. ConClusions: ACS patients treated with prasugrel had time-to-
readmission and resource utilization outcomes equivalent to what they would have 
been if treated with clopidogrel.
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oBjeCtives: Cardiac rhythm management devices (CRMD’s) have proven their clini-
cal effectiveness for patients with heart rhythm disorders. Little is known about 
safety and complication rates during implantations of these devices. This study 
demonstrated the complications rates related to implantations of CRMD’s, and 
estimated the additional hospital stay and cost associated with managing these 
complications. Methods: During a period of one year in total 464 consecutive 
recipients were subjected to CRMD’s implantation and furthermore were recruited 
and followed up for 2 years. Finally, data were analyzed for 398 patients who com-
pleted the two year’s follow up, resulting in a total of 796 patient-years. Results: 
From the 201 patients with initial pacemaker (PM) implantations, 6 (2,99 %) patients 
had seven complications (5 patients had lead’s dislodgement, 1 of them twice and 1 
patient developed pocket infection), while from the 117 PMs replacements 1 (0,85 %) 
patient developed a complication (pocket erosion). 2 patients with complication (1 
with an initial PM and 1 with replacement) died before they complete the follow up 
from reasons unrelated to cardiac causes. There weren’t any complications neither 
in initial implantations (69 patients) nor in replacements (11 patients) of implant-
able cardioverter defibrillator (ICD). The average prolongation of the hospital stay 
was 7 days ranging from 1 to 35 days, resulting in 17.411 € of total additional direct 
hospital cost. ConClusions: This study provides relatively low rates of compli-
cations in patients subjected to PMs implantation, initial or replacement, in our 
center compared with others studies. In the case of ICD implantations, initials or 
replacements, there weren’t any complication. The additional hospitalization days 
and cost attributed to these complications depends on the nature of complication.
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oBjeCtives: Unlike rivaroxaban, warfarin requires laboratory monitoring to docu-
ment achievement of international normalized ratio goal, thereby potentially pro-
longing a patient’s hospital length of stay (LOS). The study objective was to compare 
hospital LOS among hospitalized non-valvular atrial fibrillation (NVAF) patients 
using rivaroxaban versus warfarin in a real-world setting. Methods: A retrospec-
tive claims analysis was conducted using the Premier Perspective Comparative 
Hospital Database from 11/2010 to 9/2012. Adult patients were included in the study 
if they had an index hospitalization for NVAF. Patients initiating rivaroxaban dur-
ing hospitalization were matched with up to 4 warfarin users by propensity score 
analyses. Similar matched sub-analyses were conducted for patients who (1) had 
pre-treatment use of parenteral anticoagulants, and (2) were administered their oral 
anticoagulants on day 3 of their hospital stay or later. Comparison of hospital LOS 
was assessed using generalized estimating equations. Results: The characteristics 
of the matched cohorts were well balanced. Among the matched rivaroxaban and 
warfarin users (2,809 and 11,085 patients, respectively), the mean age of the cohorts 
was 71 years and 49% were females. The average [median] hospital LOS for rivaroxa-
ban patients was 4.5 [3] days compared to 5.3 [4] days for the warfarin cohort. The 
mean difference in hospital LOS of 0.81 days was found to be significant at p< 0.01. 
In the sub-analyses of patients with pre-treatment use of parenteral anticoagulants, 
the average hospital LOS was found to be 1.38 days shorter (p< 0.01) for the rivar-
oxaban group as compared to the warfarin group. Patients who were administered 
rivaroxaban on day 3 of their hospital stay or later had a 1.72 day shorter LOS as 
compared to their matched warfarin counterparts (p< 0.01). ConClusions: This 
study suggests that NVAF patients receiving rivaroxaban have significantly lower 
hospital length of stay as compared to patients receiving warfarin.
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oBjeCtives: Rivaroxaban was shown to be effective in reducing the risk of stroke 
and systemic embolism in patients with nonvalvular atrial fibrillation (AF) in a 
randomized controlled trial setting. The study objective was to assess real-world 
safety, effectiveness, and persistence of rivaroxaban and warfarin in nonvalvular AF 
patients. Methods: Health care claims from Symphony Health Solutions’ Patient 
Transactional Datasets from 5/2011-7/2012 were analyzed. Adult patients newly 
initiated on rivaroxaban or warfarin, with ≥ 2 AF diagnoses (ICD-9-CM: 427.31), and 
a CHADS2 score ≥ 1 during the 180-day baseline period were included. Cohorts 
were matched 1:4 using propensity score methods. Study outcomes were major 
bleeding, intracranial hemorrhage (ICH), gastrointestinal (GI) bleeding, composite 
stroke and systemic embolism, and venous thromboembolism (VTE) events (deep 
vein thrombosis [DVT] and pulmonary embolism [PE]). Cox proportional hazard 
models were used to compare event and persistence rates. Results: The matched 
sample included 3,654 rivaroxaban and 14,616 warfarin patients. Matching was 
adequate, with all standardized differences in patient characteristics < 10%. Mean 
age of both cohorts was 73 years; 51% were female. The mean (SD) drug exposure 
for the rivaroxaban and warfarin cohorts was 83 (58.0) and 114 (70.2) days, respec-
tively. No significant differences were observed for bleeding, and the composite 
stroke and systemic embolism outcomes, although rivaroxaban users were associ-
ated with significantly fewer VTE events (hazard ratio [HR] = 0.46, 95% confidence 
interval [CI]: 0.23-0.91, p= 0.0250) compared to warfarin users. Rivaroxaban was also 
associated with a significantly lower risk of treatment non-persistence (HR= 0.66; 
95%CI: 0.60-0.72, p< 0.001). ConClusions: This analysis suggests that rivaroxaban 
